louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01978080: Continuous Tremor Assessment During Daily Activities
Official title: ETSense: Adaptive Portable Essential Tremor Monitor - Symptomatic Impact Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Essential Tremor
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
Collaborators: name: Rush University Medical Center
name: Baylor College of Medicine
name: National Institute on Aging (NIA)
First posted: 2013-11-07
Enrollment: 39
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The specific aim of this study is to evaluate if tremor severity and quality of life can be improved more using continuous home monitoring along with traditional assessments versus traditional assessments alone.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with essential tremor
* Currently taking medication to control tremor

Exclusion Criteria:

* Cognitive limitations that prevent comprehension or execution of study protocol

Primary outcomes:
measure: Clinical Global Impression-Change Scale score
timeFrame: End of Month 1, End of Month 2, End of Month 3
Secondary outcomes:
measure: Clinical Global Impression-Severity Scale Score
timeFrame: Enrollment, End of Month 1, End of Month 2, End of Month 3
measure: Washington Heights Inwood Genetic Study of Essential Tremor (WHIGET) Tremor Rating Scale
timeFrame: Enrollment, End of Month 1, End of Month 2, End of Month 3
measure: Quality of Life in Essential Tremor Questionnaire
timeFrame: Enrollment, End of Month 1, End of Month 2, End of Month 3
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
Study officials:
affiliation: Great Lakes NeuroTechnologies
name: Dustin Heldman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06095180: Comparison of Ultrasound-guided Steroid Injection and Dry Needling in Piriformis Muscle Syndrome
Official title: Comparison of Efficacy of Ultrasound-Guided Steroid Injection and Dry Needling in Piriformis Muscle Syndrome
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Piriformis Muscle Syndrome
Keywords: piriformis syndrome
steroid injection
dry needling
exercise
Lead sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
Sponsor class: OTHER
First posted: 2023-10-23
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to to compare its effectiveness ultrasound-guided steroid injection, dry needling treatments and exercises in patients diagnosed with piriformis syndrome.

Detailed description: Piriformis syndrome is a painful entrapment neuropathy caused by compression of the sciatic nerve under the piriformis muscle. The most common cause is myofascial pain syndrome. There is no gold standard treatment for piriformis syndrome. The main purpose of treatment methods is to reduce local pain, muscle tension and spasm. This work; it will contribute to the literature by comparing steroid, dry needling and exercise treatments in patients with piriformis syndrome.

Eligibility criteria: Inclusion Criteria:

1. Age between 18-60,
2. Hip pain for ≥1 month
3. Local piriformis pain with prolonged sitting (\>20 minutes) and increased sensitivity
4. Patients with suspected piriformis syndrome based on clinical maneuvers
5. Signing and informed consent from showing consent to participate in the study

Exclusion Criteria:

1. Hip surgery
2. Lumbar disc disease
3. History of inflammatory hip disease
4. Medical treatment for pain is started
5. Neurological deficit
6. Breastfeeding or pregnant
7. Allergy to local anesthetic
8. Use of anticoagulants
9. Body mass index \>35
10. Active psychiatric illness
11. Uncontrolled hypertension and diabetes mellitus disease
12. Noncompensated chronic lung/heart/renal failure
13. History of vascular/tumoral disease

Primary outcomes:
measure: Visual Analogue Scale (VAS) (Sitting)
timeFrame: at baseline and change from baseline VAS (sitting) at 4 weeks and 12 weeks
measure: Visual Analog Scale (VAS) (Resting)
timeFrame: at baseline and change from baseline VAS (resting) at 4 weeks and 12 weeks
measure: Visual Analog Scale (VAS) (Movement)
timeFrame: at baseline and change from baseline VAS (movement) at 4 weeks and 12 weeks
Secondary outcomes:
measure: Oswestry disability index (ODI)
timeFrame: at baseline and change from baseline ODI at 4 weeks and 12 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Ankara Gaziler Physical Medicine and Rehabilitation Education and Research Hospital
name: Ayşenur Şimşek Yağlıoğlu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04845880: SARS Cov_2 Incidence of Healthy Health Workers
Official title: Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: SARS COV-2 IgG Levels on Health Workers
Lead sponsor: Baskent University
Sponsor class: OTHER
Collaborators: name: Hikmet Eda Aliskan
name: Hatice Hale Gumus
name: Ilker Odemis
name: Zuhal Ekici Unsal
First posted: 2021-04-15
Enrollment: 182
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.


Eligibility criteria: Inclusion Criteria:

Healthy Health Workers - SARS COV-2 PCR (-)

Exclusion Criteria:

Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

Primary outcomes:
measure: Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Adana Dr. Turgut Noyan Application and Research Center
Study officials:
References:
citation: Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016. Epub 2020 Feb 26.
citation: Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
Clinical trial NCT04162080: Kayak Polo Athletes
Official title: Observational Study in Kayak Polo Athletes.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Athletes
Keywords: kayak polo
Lead sponsor: University of Valencia
Sponsor class: OTHER
First posted: 2019-11-14
Enrollment: 40
Sex: ALL
Minimum age (years): 16
Maximum age (years): 30
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Observational cross-sectional study

Brief summary: Kayak polo (KP) is a sport that, as a breviary, can be defined as the union between water polo and canoeing. The objective of this study is to compare anthropometric parameters, joint assessment, strength and functional capacity between two groups of KP players from the Valencian Community. The sample will be divided into a Sub21 group and a Senior group. Anthropometric variables (body mass index \[BMI\], percentage of fat mass, waist - hip index \[CHF\], body perimeters ...), shoulder assessment (Range of movement in rotations, Scapular Dyskinesis Test \[SDT\]) will be assessed. glenohumeral instability ...), hip assessment (modified Thomas test), strength (Hand Grip Strength test and upper limb thrust), lower limb power (Counter Movement Jump \[CMJ\]) and functional capacity (1 'push-ups for limbs upper and 1 'Sit-to-Stand test for lower limbs).


Eligibility criteria: Inclusion Criteria:

* kayak polo athletes

Exclusion Criteria:

* other sports
* current injuries the previous 6 months

Primary outcomes:
measure: Weight and percentage of fat mass
timeFrame: 1 day
measure: Skin fold
timeFrame: 1 day
measure: Shoulder ROM
timeFrame: 1 day
Secondary outcomes:
measure: Scapular dyskinesia
timeFrame: 1 day
measure: Glenohumeral apprehension test
timeFrame: 1 day
measure: Impingement subacromial (SAPS)
timeFrame: 1 day
measure: Shortening in hip flexion
timeFrame: 1 day
measure: Clamping force in upper limbs
timeFrame: 1 day
measure: Thrust force in upper limbs
timeFrame: 1 day
measure: Movement Jump (CMJ) or Countermovement Jump
timeFrame: 1 day
measure: Functional capacity in lower limbs
timeFrame: 1 day
measure: Functional ability in upper limbs
timeFrame: 1 day
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: Gemma Espí
city: Valencia
country: Spain
facility: Gemma v. Espí López
Study officials:
affiliation: Faculty of Physiotherapy. University of Valencia
name: Gemma V Espí-López, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06825780: Short Term Outcomes of Primary Percutaneous Coronary Intervention (PCI) Patients Presented with Acute Heart Failure in Assuit University Heart Hospital
Official title: Short Term Outcomes of Primary Percutaneous Coronary Intervention (PCI) Patients Presented with Acute Heart Failure in Assuit University Heart Hospital
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Primary Percutaneous Coronary Intervention
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-02-13
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: assiut university heart hospital

Brief summary: Observational study outcome of PCI in patients presented with acute heart failure


Eligibility criteria: Inclusion Criteria:

* age more than 18 years
* acute heart failure
* PCI

Exclusion Criteria:

* NSTEMI
* end stage renal disease

Primary outcomes:
measure: hospital mortality and complication post PCI
timeFrame: within 3 month
Secondary outcomes:
measure: major adverse cardiac events
timeFrame: within 3 month
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Heart Hospital
state: Heart Hospital
Study officials:
affiliation: staff
name: doaa fouad abdelgaoad, staff
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lembo NJ, Karmpaliotis D, Kandzari DE. CTO PCI Procedural Planning. Interv Cardiol Clin. 2012 Jul;1(3):299-308. doi: 10.1016/j.iccl.2012.04.002. Epub 2012 Jun 5.
Clinical trial NCT00581880: Measuring Hope and Hopelessness in Cancer
Official title: Measuring Hope and Hopelessness in Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Advanced Cancer
Keywords: end stage
Terminally Ill
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Fordham University
name: Calvary Hospital, Bronx, NY
name: Peter MacCallum Cancer Centre, Australia
First posted: 2007-12-28
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects will be recruited in equal numbers from Memorial Hospital and Calvary Hospital or Peter MacCallum Cancer Centre at each stage of data collection.

Brief summary: The purpose of this study is to develop an accurate and useful way of measuring patients' thoughts and feelings about hope and hopelessness as they relate to their illness. Doctors and psychologists from Memorial Sloan-Kettering Cancer Center, Calvary Hospital, the Peter MacCallum Cancer Centre, and Fordham University are working together to design a new measure. Findings from this research will help us study the nature of illness and develop improved methods of diagnosis and treatment. We hope what we learn from you will help us learn more about how to care better for patients with cancer and other severe illnesses.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older.
* Patients who are able to understand verbal and written English.
* Diagnosis of cancer.
* Patients with advanced cancer receiving ambulatory or inpatient care at Memorial Sloan-Kettering Cancer Center in New York City. Patients at Calvary Hospital and Peter MacCallum Cancer Centre admitted for palliative care will also be eligible for participation in this study

Exclusion Criteria:

* The presence of a psychotic mental disorder (e.g., Bipolar Disorder, Schizophrenia, Schizo-affective illness, psychosis due to substance abuse) as indicated in medical chart.
* Cognitive impairment so severe (i.e., Mini-Mental State exam score of less than 20) that, in the opinion of the Principal Investigator or Project Coordinator, would interfere with a patient's ability to give informed consent for research.

Primary outcomes:
measure: To explore and better understand the construct of hopelessness as it applies to terminally ill cancer patients.
timeFrame: conclusion of study
measure: To develop a brief self-report measure of hopelessness grounded in the construct of hopelessness as it applies to terminally ill cancer patients.
timeFrame: conclusion of study
Secondary outcomes:
measure: To establish the reliability and validity of this newly developed measure of hopelessness in a large sample of terminally ill cancer patients.
timeFrame: conclusion of study
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: William Breitbart, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00171080: VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
Official title: A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Keywords: Hypertension
Valsartan
Dialysis
Renal Disease
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-15
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the efficacy, safety and tolerability of valsartan 80 mg (with a starting dose of 40 mg) to irbesartan 150 mg (with a starting dose of 75 mg) in patients on long-term haemodialysis with mild to moderate increased mean supine systolic blood pressure (MSSBP).


Eligibility criteria: Inclusion Criteria:

* Patients with mild and moderate hypertension defined by a MSSBP ≥ 140 mmHG and \< 180 mmHG at Visits 1 and 2 for treated and untreated patients
* Chronic hemodialysis for at least 6 months prior to Visit 1 as substitution therapy.
* If treated with epoetin: patients with a stable hematocrit ≤ 40% (± 5%).

Exclusion Criteria:

* Inability to discontinue angiotensin II receptor blockers (ARBs) safely for a period of 1 week, as required by the protocol.
* Treatment with more than 3 different compounds for the treatment of hypertension at Visit 1.
* Atrial fibrillation

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change from baseline in systolic blood pressure after 4 weeks
Secondary outcomes:
measure: Change from baseline in diastolic blood pressure after 4 weeks
measure: Systolic blood pressure less than 100 mmHg with or without symptoms of low blood pressure
measure: Adverse events and clinical laboratory abnormal results
measure: Change from baseline in average 24-hour ambulatory blood pressure after 4 weeks
measure: Change from baseline in daytime and nighttime ambulatory blood pressures after 4 weeks
Other outcomes:
Locations:
city: Investigative Centers
country: Germany
city: Basel
country: Switzerland
facility: Novartis Pharmaceuticals
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Leidig M, Bambauer R, Kirchertz EJ, Szaba T, Handrock R, Leinung D, Baier M, Schmieder RE. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008 Jun;69(6):425-32. doi: 10.5414/cnp69425.
Clinical trial NCT02279680: Associative Memory in Adults With an Autism Spectrum Disorder
Official title: The Associative Memory in Autism Spectrum Disorders Without Intellectual Disability
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Autistic Disorder
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
First posted: 2014-10-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The objective of this multidisciplinary project is to explore the deficit of associative memory in ASD (Autistic Spectrum Disorder) that could result from abnormal brain connectivity. The hypothesis of abnormal functioning of the fronto-hippocampal network has been evocated but has never been tested. Hence, the present project will include two complementary assessments conducted on a group of adults aged from 18 to 30 with ASD compared to a control group matched in chronological age and intellectual quotient. The first assessment is devoted to the study of associative memory and its EEG correlates and the second focused on the investigation of perceptual strategies related to associative memory using the technique of Eye-tracking. Both behavioral and imaging data would provide new insights on the relationship between perception and memory in ASD.


Eligibility criteria: Inclusion Criteria:

* Adult between 18 and 30 years old
* right handed
* affiliated to the french national health care system
* ASD only for the group of patients

Exclusion criteria :

* mental retardation
* schizophrenia
* ADHD
* brain injury with lost of consciousness
* neurological disease

Primary outcomes:
measure: The associative memory index
timeFrame: 2 years
Secondary outcomes:
measure: theta and gamma oscillations during the associative memory task
timeFrame: 2 years
Other outcomes:
Locations:
city: Caen
country: France
facility: UMR1077 Inserm/EPHE/UCBN
Study officials:
affiliation: University Hospital, Caen
name: Jean-Marc BALEYTE, PU-PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06374680: C3 Laminectomy With Cervical Laminoplasty
Official title: Randomized Controlled Trial: Comparison of Radiological and Axial Pain Outcome Between C3-6 Laminoplasty and C3 Laminectomy With Cervical Laminoplasty
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Neck Pain
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2024-04-19
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with cervical stenosis who should undergo cervical laminoplasty

Brief summary: 1. Background In cervical stenosis, cervical laminoplasty from the third to sixth cervical vertebrae is widely used. However, the muscles attached to the C2, which play an important role in the movement of our neck, are frequently damaged during the C3 laminoplasty. In contrast, cervical spine surgery through the removal of the C3 is thought to give less damage to the muscles attached to the C2.
2. Purpose The aim of this study was to compare the prospective randomized comparison of these two surgical methods.
3. Hypothesis There is no difference in the cervical length and overall cervical angle between 1 month, 3 months, 6 months, and 12 months postoperatively between C3 laminectomy with C4-6 laminoplasty and C3-6 laminoplasty.

Detailed description: Surgery is performed under general anesthesia as before, followed by posterior cervical incision. In one group, the cervical spine of the C3 is removed using a drill and punch and C4-6 laminoplasty will be performed. In the other group, C3-6 laminoiplasty will be performed. Postoperative suturing and subject management are the same as existing patient care policies. Follow-up is performed at 1 month, 3 months, 6 months, 12 months, and 1 year after surgery at the outpatient clinic and x-ray is taken at each outpatient follow-up. The degree of the neck pain is measured using NDI and VAS for each outpatient f/u.

Eligibility criteria: Inclusion Criteria:

* cervical stenosis

Exclusion Criteria:

* metastatic tumor
* fracture
* previous cervical spine surgery (posterior approach)

Primary outcomes:
measure: neck pain
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Chun Kee Chung, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: